CN112236430A - 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途 - Google Patents

一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途 Download PDF

Info

Publication number
CN112236430A
CN112236430A CN201980034774.7A CN201980034774A CN112236430A CN 112236430 A CN112236430 A CN 112236430A CN 201980034774 A CN201980034774 A CN 201980034774A CN 112236430 A CN112236430 A CN 112236430A
Authority
CN
China
Prior art keywords
substituted
group
unsubstituted
chloro
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980034774.7A
Other languages
English (en)
Other versions
CN112236430B (zh
Inventor
柳红
耿美玉
周宇
丁健
方非非
艾菁
李建
彭霞
蒋华良
季寅淳
陈凯先
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN112236430A publication Critical patent/CN112236430A/zh
Application granted granted Critical
Publication of CN112236430B publication Critical patent/CN112236430B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明提供了一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途，具体地，本发明提供了一种具有如式(I)所示结构的化合物(各基团定义如说明书中所述)。该化合物可以作为AXL抑制剂，用于制备治疗肿瘤的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980034774.7A 2018-05-21 2019-05-21 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途 Active CN112236430B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810491115.3A CN110511218A (zh) 2018-05-21 2018-05-21 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途
CN2018104911153 2018-05-21
PCT/CN2019/087867 WO2019223704A1 (zh) 2018-05-21 2019-05-21 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途

Publications (2)

Publication Number Publication Date
CN112236430A true CN112236430A (zh) 2021-01-15
CN112236430B CN112236430B (zh) 2023-02-17

Family

ID=68615979

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810491115.3A Pending CN110511218A (zh) 2018-05-21 2018-05-21 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途
CN201980034774.7A Active CN112236430B (zh) 2018-05-21 2019-05-21 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810491115.3A Pending CN110511218A (zh) 2018-05-21 2018-05-21 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途

Country Status (11)

Country Link
US (1) US20210221807A1 (zh)
EP (1) EP3798218A4 (zh)
JP (1) JP7339282B2 (zh)
KR (1) KR102658011B1 (zh)
CN (2) CN110511218A (zh)
AU (1) AU2019273337B2 (zh)
BR (1) BR112020023870A2 (zh)
CA (1) CA3101223A1 (zh)
EA (1) EA202092766A1 (zh)
SG (1) SG11202011638WA (zh)
WO (1) WO2019223704A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
CN113683629B (zh) * 2020-05-18 2023-07-04 北京范恩柯尔生物科技有限公司 取代的杂芳基化合物及其组合物和用途
WO2024039842A2 (en) * 2022-08-19 2024-02-22 National Health Research Institutes Inhibitors of tam receptors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248059A (zh) * 2005-04-27 2008-08-20 安姆根有限公司 作为蛋白激酶抑制剂的取代的酰胺衍生物
WO2010039248A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
CN102086211A (zh) * 2009-12-08 2011-06-08 深圳市东阳光实业发展有限公司 作为蛋白激酶抑制剂的芳杂环化合物
CN102245595A (zh) * 2008-10-14 2011-11-16 株式会社新药 作为蛋白质激酶抑制剂的杂环化合物
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN104974162A (zh) * 2014-04-09 2015-10-14 广东东阳光药业有限公司 双环吡唑酮化合物及其使用方法和用途
US20170349583A1 (en) * 2014-12-25 2017-12-07 Ono Pharmaceutical Co., Ltd. Quinoline derivative

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248059A (zh) * 2005-04-27 2008-08-20 安姆根有限公司 作为蛋白激酶抑制剂的取代的酰胺衍生物
WO2010039248A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
CN102245595A (zh) * 2008-10-14 2011-11-16 株式会社新药 作为蛋白质激酶抑制剂的杂环化合物
CN102086211A (zh) * 2009-12-08 2011-06-08 深圳市东阳光实业发展有限公司 作为蛋白激酶抑制剂的芳杂环化合物
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN104974162A (zh) * 2014-04-09 2015-10-14 广东东阳光药业有限公司 双环吡唑酮化合物及其使用方法和用途
US20170349583A1 (en) * 2014-12-25 2017-12-07 Ono Pharmaceutical Co., Ltd. Quinoline derivative

Also Published As

Publication number Publication date
EP3798218A4 (en) 2022-03-02
AU2019273337A1 (en) 2021-01-21
CN112236430B (zh) 2023-02-17
KR20210011988A (ko) 2021-02-02
JP2021524471A (ja) 2021-09-13
EA202092766A1 (ru) 2021-07-08
KR102658011B1 (ko) 2024-04-17
SG11202011638WA (en) 2020-12-30
BR112020023870A2 (pt) 2021-02-09
CN110511218A (zh) 2019-11-29
CA3101223A1 (en) 2019-11-28
US20210221807A1 (en) 2021-07-22
EP3798218A1 (en) 2021-03-31
JP7339282B2 (ja) 2023-09-05
WO2019223704A1 (zh) 2019-11-28
AU2019273337B2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP4548642B2 (ja) プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン
KR101656382B1 (ko) 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
WO2013033981A1 (zh) 一类2,7-萘啶衍生物及其制备方法和应用
AU2014250836B2 (en) Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
EP2995618B1 (en) [1,2,4]triazol [4,3-a]pyridine derivate, preparation method therefor or medical application thereof
US9353062B2 (en) Substituted quinolines as bruton's tyrosine kinases inhibitors
TW201619150A (zh) 用於調節ｅｇｆｒ突變型激酶活性的化合物及組成物
JP2013519725A (ja) 二環式化合物および二重ｃ−ＳＲＣ／ＪＡＫ阻害剤としてのそれらの使用
KR102229471B1 (ko) 헤테로사이클 유도체 및 그의 용도
US9938274B1 (en) Naphthyridine compounds, medical combinations and use thereof
CN112236430B (zh) 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途
WO2005115145A2 (en) Quinone substituted quinazoline and quinoline kinase inhibitors
EP1268487B1 (en) Tricyclic protein kinase inhibitors
US11427559B2 (en) Substituted quinolines useful as kinase inhibitors
KR101937529B1 (ko) 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN112236422B (zh) 喹唑啉类化合物作为egfr三突变抑制剂及其应用
TWI565698B (zh) 喹啉化合物，其製造方法及用途
JP2024515204A (ja) ヘテロアリール誘導体化合物およびその用途
KR20120053648A (ko) 신규 티에노피리미딘 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034445

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant